Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
about
IBS with intestinal microbial dysbiosis: a new and clinically relevant subgroup?Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.New Options in Constipation Management.New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond.
P2860
Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Lubiprostone: pharmacokinetic, ...... nant irritable bowel syndrome.
@en
type
label
Lubiprostone: pharmacokinetic, ...... nant irritable bowel syndrome.
@en
prefLabel
Lubiprostone: pharmacokinetic, ...... nant irritable bowel syndrome.
@en
P2860
P1476
Lubiprostone: pharmacokinetic, ...... nant irritable bowel syndrome.
@en
P2860
P304
P356
10.1517/17425255.2013.876410
P407
P577
2014-01-03T00:00:00Z